Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

In Oral Maintenance Therapy in AML, Do All Roads Lead to the Epigenome?

Maintenance therapy to reduce relapse of acute myeloid leukemia (AML) and prolong overall survival (OS) has been explored since the 1960s.1 Chemotherapeutic and immunologic...

Azacitidine Tablets Approved for AML Following Chemotherapy

The FDA has approved azacitidine tablets, formerly known as CC-486, for the continued treatment of adults with acute myeloid leukemia (AML) who achieved first...

Venetoclax Combination Granted Full Approval for Newly Diagnosed AML

Venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) has been approved for the treatment of adults with newly diagnosed acute myeloid leukemia...

Evaluating Post-Transplant Sorafenib Maintenance in FLT3-Mutated AML

For patients with acute myeloid leukemia (AML) and an FLT3-ITD mutation, maintenance treatment with the multitargeted tyrosine kinase inhibitor (TKI) sorafenib significantly prolonged relapse-free...
WIB_icon

Is Haploidentical Better Than Cord Blood Transplantation in Leukemia and Lymphoma?

Allogeneic hematopoietic cell transplantation with cord blood or haploidentical bone marrow extend access to transplantation for patients who lack a human leukocyte antigen (HLA)–matched...
WIB_icon

Geriatric Assessment Identifies Risk Factors for Worse Survival in Older Adults With AML

Older patients with acute myeloid leukemia (AML) who undergo post-remission therapy may be at risk of poor survival if they present with impaired physical...
How I Treat In Brief

How I Treat in Brief: Acute Myeloid Leukemia in the Era of New Drugs

Courtney D. DiNardo, MD, and Andrew H. Wei, MD, review recently approved therapies for acute myeloid leukemia and the treatment challenges they present. This material...
On location

Decitabine Plus Venetoclax Outperforms Intensive Chemotherapy Across Risk Groups

For older and unfit patients with acute myeloid leukemia (AML), venetoclax plus hypomethylating agents (HMAs) have been established as a standard of care and...

Indication Expanded for Gemtuzumab Ozogamicin

The FDA has extended the indication of gemtuzumab ozogamicin to include pediatric patients aged 1 month or older with newly diagnosed CD33-positive acute myeloid...
On location

A New CAR T-Cell Target for T-Cell Acute Lymphocytic Leukemia?

The anti-CD7 chimeric antigen receptor (CAR) T-cell therapy TruUCAR GC027 demonstrated promising efficacy in treating adults with relapsed or refractory T-cell acute lymphoblastic leukemia...